The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global clinical diagnostics market size reached US$ 76.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 124.7 Billion by 2028, exhibiting a growth rate (CAGR) of 5.67% during 2023-2028.
Clinical diagnostics refer to the process of detecting, identifying and monitoring a disease through signs, symptoms, health history, and physical examination of a patient. They comprise manufacturing, developing, and selling automated test systems, informatics systems, test kits and specialized quality controls. They assist in disease management to improve health and the overall well-being of patients. They also aid in the stratification of patients with diverse diseases to provide them with targeted therapy. In addition, they can predict therapeutic efficacy, improve the effectiveness of treatments and avoid long-term complications for patients. As a result, clinical diagnostics find extensive applications in the hospital laboratory, diagnostic laboratory, and point-of-care testing across the globe.
At present, there is a rise in the prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, around the world. This, along with the growing adoption of automated platforms for disease prevention, detection, and management, represents one of the key factors driving the market. Moreover, there is an increase in the practice of lipid panel tests to measure total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, HDL ratio, and non-HDL cholesterol. This, coupled with the rising mortality rate due to increasing cardiovascular diseases, is propelling the growth of the market. Besides this, the rising awareness among individuals about the benefits of laboratory tests is offering lucrative growth opportunities to industry investors. Apart from this, the increasing utilization of clinical diagnostics by healthcare providers to develop targeted therapies through specific and sensitive diagnostic tests is bolstering the growth of the market. Additionally, the escalating demand for personalized medicine among patients is positively influencing the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global clinical diagnostics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on test, product and end user.
Breakup by Test:
Breakup by Product:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Qiagen N.V., Quest Diagnostics Incorporated, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2022|
|Segment Coverage||Test, Product, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Qiagen N.V., Quest Diagnostics Incorporated, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global clinical diagnostics market was valued at US$ 76.2 Billion in 2022.
We expect the global clinical diagnostics market to exhibit a CAGR of 5.67% during 2023-2028.
The sudden outbreak of the COVID-19 pandemic has led to the increasing deployment of clinical diagnostics for diagnosing the coronavirus infection among individuals.
The rising prevalence of numerous chronic diseases, such as cancer, heart disease, stroke, diabetes, etc., along with the growing adoption of automated platforms for disease prevention, detection, and management, is primarily driving the global clinical diagnostics market.
Based on the test, the global clinical diagnostics market can be categorized into lipid panel, liver panel, renal panel, complete blood count, electrolyte testing, infectious disease testing, and others. Currently, lipid panel accounts for the majority of the total market share.
Based on the product, the global clinical diagnostics market has been segregated into instruments, reagents, and others. Among these, instruments currently hold the largest market share.
Based on the end user, the global clinical diagnostics market can be bifurcated into hospital laboratory, diagnostic laboratory, point-of-care testing, and others. Currently, diagnostic laboratory exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global clinical diagnostics market include Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Qiagen N.V., Quest Diagnostics Incorporated, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at